Apalutamide

Apalutaminde is an AR inhibitor used in the treatment of non metastasis castrated prostate cancer (nm-crpc).

Apalumide is a second generation of high selective androgen receptor antagonists, and its affinity with androgen receptor is more than 5 times that of the first generation androgen receptor antagonist. A phase III study involving 1207 patients with non metastatic castration resistance to prostate cancer has shown that apalumide significantly prolonged the metastasis free survival of patients compared with placebo (40.5vs16.2 months). It is used to treat prostate cancer with non metastasis (prostate cancer cell non-proliferation) castration resistance (disease is still progressing after hormone therapy). Because abitron is only used to treat metastatic castration to fight prostate cancer, apalumide will provide new impetus for Johnson and Johnson's prostate cancer business.